PANCREATIC CANCER RESEARCH FUND — grant history
Latest income
£1.5m
Grants listed (FY2025)
1
Listed grants total
£121k
Accounts grants total
£703k
listed grants do not fully reconcile with the accounts total — list may be partialextracted from its FY2025 accounts
What changed: FY2024 → FY2025
| Change | Grantee | FY2024 | FY2025 |
|---|---|---|---|
| new | Queen Mary University of London | — | £121k |
| not listed | Professor John Marshall, Queen Mary University of London | £98k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Queen Mary University of London | FY2025 | £121k | One-year cost extension for the project ‘The integrin αvβ6 drives PDAC metastasis: mechanisms and therapeutic insights’ |
| Professor John Marshall, Queen Mary University of London | FY2024 | £98k | One-year cost extension for the project ‘The integrin avB6 drives PDAC metastasis: mechanisms and therapeutic insights’ |
| PCRF Tissue Bank | FY2023 | £364k | continued support and development of the PCRF Tissue Bank |
| Earlier grantees | FY2023 | £182k | Additional grant payments (continuing payments to earlier grantees) |
| Cambridge University | FY2022 | £269k | Additional grant payments |
| Imperial College London | FY2022 | £220k | Personalised therapy for pancreatic adenocarcinoma without toxicity through protease-sensitive masking and tumour targeting interleukin-12 |
| Queen Mary University London | FY2022 | £220k | Anti-Histamines as Novel Therapeutics in Pancreatic Cancer |
| Barts Cancer Institute, Queen Mary University, London | FY2022 | £220k | Additional grant payments |
| Oxford University | FY2022 | £220k | Additional grant payments |
| Cardiff University School of Medecine | FY2022 | £219k | Establishing "organoid hospitals" as preclinical models to evaluate precision virotherapies |
| London School of Hygiene and Tropical Medecine | FY2022 | £219k | Additional grant payments |
| University College London | FY2022 | £219k | Characterising immune surveillance and dysfunction in early stage pancreatic cancer |
| University of Liverpool | FY2022 | £216k | Defining the molecular mechanisms by which MIF impacts liver metastasis in pancreatic cancer and exploring its therapeutic application |
| Cambridge University | FY2022 | £210k | Additional grant payments |
| Barts Cancer Institute, Queen Mary University, London | FY2022 | £65k | Additional grant payments |
| Barts Cancer Institute, Queen Mary University, London | FY2021 | £220k | The integrin avb6 drives PDAC metastasis: mechanisms and therapeutic insights (Marshall, John) |
| Barts Cancer Institute, Queen Mary University, London | FY2021 | £220k | Development of an enhanced oncolytic Vaccinia virus-based therapeutic regime that simultaneously targets multiple elements of the tumour promoting microenvironment in pancreatic cancer (Wang, Yaohe) |
| Cambridge University | FY2021 | £220k | Designing new strategies to target the tumour-promoting roles of pancreatic cancer fibroblasts (Biffi, Giulia) |
| London School of Hygiene and Tropical Medecine | FY2021 | £219k | A risk score for pancreatic cancer diagnosis using machine learning techniques applied to linked routine data: full case-control study and economic evaluation (Woods, Laura) |
| Cambridge University | FY2021 | £210k | Investigating subtype-specific therapeutic targets in the FOXA1 interactome of PDAC (Carroll, Jason) |
| Barts Cancer Institute, Queen Mary University, London | FY2021 | £201k | Retinoic acid regulation of pancreatic stellate cell phenotype (Kocher, Hemant) |
| Oxford University | FY2021 | £65k | Targeting immunotherapy to the pancreatic tumour microenvironment using oncolytic viruses to direct T cell cytotoxicity to stress-induced ligands (Seymour, Len) |